News

Jim Mellon-backed biotech to join Aim

Jim Mellon-backed biotech to join Aim
An experimental cancer drug discovered at Oxford University is the focus of a new UK biotech company to be listed in London this week led by two veterans of Bristol-Myers Squibb, the large US pharmaceuticals group.